These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1011 related articles for article (PubMed ID: 33357452)

  • 1. Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade.
    Srivastava S; Furlan SN; Jaeger-Ruckstuhl CA; Sarvothama M; Berger C; Smythe KS; Garrison SM; Specht JM; Lee SM; Amezquita RA; Voillet V; Muhunthan V; Yechan-Gunja S; Pillai SPS; Rader C; Houghton AM; Pierce RH; Gottardo R; Maloney DG; Riddell SR
    Cancer Cell; 2021 Feb; 39(2):193-208.e10. PubMed ID: 33357452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models.
    Wallstabe L; Göttlich C; Nelke LC; Kühnemundt J; Schwarz T; Nerreter T; Einsele H; Walles H; Dandekar G; Nietzer SL; Hudecek M
    JCI Insight; 2019 Sep; 4(18):. PubMed ID: 31415244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis.
    Blobner J; Dengler L; Eberle C; Herold JJ; Xu T; Beck A; Mühlbauer A; Müller KJ; Teske N; Karschnia P; van den Heuvel D; Schallerer F; Ishikawa-Ankerhold H; Thon N; Tonn JC; Subklewe M; Kobold S; Harter PN; Buchholz VR; von Baumgarten L
    Cancer Immunol Immunother; 2024 Oct; 73(12):255. PubMed ID: 39358663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC.
    Harrasser M; Gohil SH; Lau H; Della Peruta M; Muczynski V; Patel D; Miranda E; Grigoriadis K; Grigoriadis A; Granger D; Evans R; Nathwani AC
    Breast Cancer Res; 2022 Jun; 24(1):39. PubMed ID: 35659040
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Stüber T; Monjezi R; Wallstabe L; Kühnemundt J; Nietzer SL; Dandekar G; Wöckel A; Einsele H; Wischhusen J; Hudecek M
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabozantinib enhances CAIX specific CAR-T cells against renal cancer by improving effector functions and augmenting tumor immune microenvironment.
    Li Q; Yang L; Li S; Zhao W; Xue Y; Lu Z; Tang J; Gao X; Zheng J; Zhang Q; Sun S
    Biochem Biophys Res Commun; 2024 Nov; 734():150781. PubMed ID: 39368372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.
    Hudecek M; Lupo-Stanghellini MT; Kosasih PL; Sommermeyer D; Jensen MC; Rader C; Riddell SR
    Clin Cancer Res; 2013 Jun; 19(12):3153-64. PubMed ID: 23620405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting.
    Srivastava S; Salter AI; Liggitt D; Yechan-Gunja S; Sarvothama M; Cooper K; Smythe KS; Dudakov JA; Pierce RH; Rader C; Riddell SR
    Cancer Cell; 2019 Mar; 35(3):489-503.e8. PubMed ID: 30889382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
    Hong M; Clubb JD; Chen YY
    Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The Construction of ROR1 Targeting Chimeric Antigen Receptor Modified T Cells and Its Killing Effect for ROR1-positive Tumor Cells].
    Chen Y; Mo ZM; Qin DY; Guo FC; Liao XL; Hu M; Chen Q; Wang YS
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Mar; 50(2):145-151. PubMed ID: 31106530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review.
    Satapathy BP; Sheoran P; Yadav R; Chettri D; Sonowal D; Dash CP; Dhaka P; Uttam V; Yadav R; Jain M; Jain A
    Front Immunol; 2024; 15():1389971. PubMed ID: 38799440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 13. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
    Qu J; Mei Q; Chen L; Zhou J
    Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in research on factors affecting chimeric antigen receptor T-cell efficacy.
    Zhou D; Zhu X; Xiao Y
    Cancer Med; 2024 Jun; 13(11):e7375. PubMed ID: 38864474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
    Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
    J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.
    Berger C; Sommermeyer D; Hudecek M; Berger M; Balakrishnan A; Paszkiewicz PJ; Kosasih PL; Rader C; Riddell SR
    Cancer Immunol Res; 2015 Feb; 3(2):206-16. PubMed ID: 25355068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
    Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
    Front Immunol; 2021; 12():665970. PubMed ID: 34475869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas.
    Huang X; Park H; Greene J; Pao J; Mulvey E; Zhou SX; Albert CM; Moy F; Sachdev D; Yee D; Rader C; Hamby CV; Loeb DM; Cairo MS; Zhou X
    PLoS One; 2015; 10(7):e0133152. PubMed ID: 26173023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
    Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
    Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice.
    Porcellini S; Asperti C; Corna S; Cicoria E; Valtolina V; Stornaiuolo A; Valentinis B; Bordignon C; Traversari C
    Front Immunol; 2020; 11():99. PubMed ID: 32117253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.